Pharmaceutical Excipients are substances other than pharmacologically active drug components, which are included in the drug manufacturing process or contained in a finished pharmaceutical product dosage form. They facilitate formulation design and perform a range of functions such as enhancing flowability, increasing lubricity, improving compressibility, etc.
Types of Product is being segmented into Organic and Inorganic Chemicals. Among these Organic chemicals, segment accounted for the most significant share of the pharmaceutical excipients market, followed by inorganic chemicals. The large share of Organic Chemicals can be attributed to the wide applications in the manufacturing of pharmaceutical drugs.
The Pharmaceutical Excipients market is expected to reach USD 10.1 Billion by the end of 2024, growing at a CAGR of around 7.5% from 2018 to 2024.
The Pharmaceutical Excipients Market is segmented by geography into North America, South America, Europe, Asia-Pacific, Middle East & Africa. Among these North America has the largest market share in Pharmaceuticals Excipients Market. Asia-Pacific is one of the upcoming markets due to advancements in the technology of new manufacturing of new excipients.
Rise in the incidence of diseases, which has increased the demand for drugs, Inventions of new excipients in the pharmaceutical industry, Advancements in the techniques and equipment for manufacturing excipients are the significant factors that are contributing to the growth of the Pharmaceutical Excipients Market.
The Pharmaceutical Excipients market is segmented on the basis of process into diluents, binders, disintegrants, glidants, lubricants, flavoring agents, coloring agents and coatings & films, By type of product into inorganic chemicals and organic chemicals and By Region into North America, Europe, Asia-Pacific, South America, Middle East & Africa.
Leading market players are currently focusing on the utilisation of functionality excipients to create controlled dosage forms of existing drugs. As many blockbuster drugs are on the verge of losing their patents, pharmaceutical companies are trying to extend patents by using functionality excipients. Moreover, companies are also trying to tackle the problem of drug toxicity, mostly observed in oncology therapy, by reducing the size of drug crystals for greater solubility and using a nano-carrier for delivering the active drug.
Azelis Company expands its presence in the Swiss market with the acquisition of Georges Walther AG to become a well-respected business partner for specialities and innovation in Switzerland. FMC Corporation announced that it had revised its operating agreements with Argentina, allowing it to expand production and completing an important step toward the intended separation of its lithium business in 2018.
Starting from $2700
Starting from $2700
Starting from $2700
Keep up-to-date with our weekly newsletter, Media Pulse.